Prognostic significance ofc-myc andAIB1 amplification in hepatocellular carcinoma
Autor: | Meng-Chao Wu, Wei-Qing Wu, Jonathan S. T. Sham, Yi Wang, Xin Yuan Guan, Weigou Zhang |
---|---|
Rok vydání: | 2002 |
Předmět: |
Cancer Research
Pathology medicine.medical_specialty Carcinoma Hepatocellular Genes myc In situ hybridization Nuclear Receptor Coactivator 3 Gene duplication Carcinoma medicine Humans Neoplasm Metastasis neoplasms In Situ Hybridization Fluorescence Microdissection Tissue microarray medicine.diagnostic_test business.industry Liver Neoplasms Gene Amplification Cancer DNA Neoplasm Prognosis medicine.disease digestive system diseases Oncology Chromosomes Human Pair 1 Hepatocellular carcinoma Disease Progression Cancer research business Transcription Factors Fluorescence in situ hybridization |
Zdroj: | Cancer. 95:2346-2352 |
ISSN: | 1097-0142 0008-543X |
Popis: | BACKGROUND Amplifications of 1q21, c-myc at 8q24.1, and AIB1 at 20q12 are genetic alterations that are detected frequently in hepatocellular carcinoma (HCC). The authors evaluated the association of these amplifications with the prognosis of patients with HCC. METHODS In the current study, amplification of 1q21, c-myc, and AIB1 was analyzed in 560 specimens from 400 patients with HCC and 20 patients with benign liver lesions using fluorescence in situ hybridization with high-throughput tissue microarray. Differences of amplification patterns were compared between small and large HCC, single nodular and multiple nodular HCC, primary and metastatic HCC, and primary and recurrent HCC. RESULTS Significant differences between single nodular and multiple nodular HCC were detected in c-myc amplification (12% vs. 38%; P < 0.01) and AIB1 amplification (16% vs. 30%; P < 0.05). More frequent c-myc amplification was detected in metastatic HCC (45%) compared with primary HCC (29%) and in recurrent HCC (60%) compared with primary HCC (38%). Similarly, more frequent AIB1 amplification was observed in metastatic HCC (41%) compared with primary HCC (23%) and in recurrent HCC (60%) compared with primary HCC (29%). However, no significant differences in 1q21 amplification were observed. CONCLUSIONS The current results strongly suggest that amplifications of the c-myc and AIB1 oncogenes are late genetic alterations in the progression of HCC and are correlated with a poor prognosis. Cancer 2002;95:2346–52. © 2002 American Cancer Society. DOI 10.1002/cncr.10963 |
Databáze: | OpenAIRE |
Externí odkaz: |